Saturday, 24 October 2020


US FDA nod to epinephrine auto-injector with audio, visual cues

14 August 2012 | Regulatory | By BioSpectrum Bureau

US FDA nod to epinephrine auto-injector with audio, visual cues

Auvi-Q is the first-and-only compact epinephrine auto-injector with audio and visual cues

Auvi-Q is the first-and-only compact epinephrine auto-injector with audio and visual cues

Singapore: The US Food and Drug Administration (FDA) has approved Auvi-Q (epinephrine injection, USP) for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. Auvi-Q is the first-and-only compact epinephrine auto-injector with audio and visual cues that guide patients and caregivers step-by-step through the injection process.

Sanofi US licensed the North American commercialization rights to Auvi-Q from Intelliject, which has retained commercialization rights for the rest of the world. "As a company committed to patient-centered care, our focus is on creating innovative solutions that make a difference in the lives of people," said Ms Anne Whitaker, president, North America Pharmaceuticals, Sanofi US. "Auvi-Q delivers on this by offering a state-of-the-art epinephrine auto-injector device that addresses the needs of patients at risk for lifethreatening allergic reactions and their caregivers."

While recently updated guidelines emphasize the importance of the life-saving role of epinephrine, surveys showed that two-thirds of patients and caregivers do not carry their epinephrine auto-injectors as recommended and nearly half worry that others will not know how to use their device during an emergency. "With this FDA approval, Auvi-Q will become the first-and-only epinephrine auto-injector that talks users through each step of the injection process," said Mr Bryan Downey, vice president, Auvi-Q, Sanofi US. "We are confident that Auvi-Q will provide the up to six million Americans at risk for anaphylaxis and their caregivers an easy-to-use, compact option with unique features to help manage a life-threatening allergic reaction."

Auvi-Q contains epinephrine, a well-established, first-line treatment for severe, lifethreatening allergic reactions that may occur as a result of exposure to allergens including nuts, shellfish, dairy, eggs, insect bites, latex and medication, among other allergens.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account